Synthesis and antitumor evaluation of novel 4-anilino-7,8-dihydropyrido[4,3-<i>d</i>
]pyrimidine-6(5<i>H</i>
)-carboxylate derivatives as potential EGFR inhibitors
作者:Dajun Zhang、Yan Yan、Ge Jin、Bo Liu、Xiaoliang Ma、Dan Han、Xiaojian Jia
DOI:10.1002/ardp.201800110
日期:2018.9
factor receptor (EGFR), HER2, and VEGFR identified compound 5a as a promising hit that exhibited considerable potency both in cellular (IC50 = 5.67, 17.04, 11.29, and 12.65 µM, respectively) and EGFR enzymatic assays (IC50 = 14.8 nM). Compound 5a was capable of down‐regulating the expression of EGFR and inhibited EGFR phosphorylation in a dose‐dependent manner, representing a potential EGFR candidate for
合成了新系列的 4-anilino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylates (5a-p, 7, and 8a-e) 并评估了它们对 A549 的抗增殖活性、HT29、H460 和 H1975 癌细胞系体外。九种化合物(5a–c、5i、5j、7、8a、8b、8i)在 A549 细胞上表现出中等到显着的细胞毒活性,IC50 值低于 18 µM,与参考吉非替尼的 IC50 值相当(IC50 = 18.44 µM) . 特别是,对表皮生长因子受体 (EGFR)、HER2 和 VEGFR 的进一步酶促分析确定化合物 5a 是一种很有前景的命中物,在细胞(IC50 分别为 5.67、17.04、11.29 和 12.65 µM)和 EGFR 中均表现出相当大的效力酶促测定 (IC50 = 14.8 nM)。